In an era of increased scrutiny and large settlements, zealous prosecutors will undoubtedly use novel methods to pursue pharmaceutical manufacturers. One area that has received significant attention is off-label promotion. According to the Food, Drug and Cosmetic Act, if a pharmaceutical manufacturer promotes its product for uses other than those included in the FDA-approved label, that manufacturer has engaged in off-label promotion, which “misbrands” prescription drugs and is expressly prohibited.
Please click here to read the full article.